Syndax Pharmaceuticals (SNDX) News Today $15.03 +0.02 (+0.13%) Closing price 04:00 PM EasternExtended Trading$15.42 +0.39 (+2.59%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SNDX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Analyzing Syndax Pharmaceuticals (NASDAQ:SNDX) and Maze Therapeutics (NASDAQ:MAZE)September 22 at 2:25 AM | americanbankingnews.comSyndax Pharmaceuticals' (SNDX) "Buy" Rating Reiterated at BTIG ResearchSeptember 21, 2025 | americanbankingnews.comSyndax Pharmaceuticals (NASDAQ:SNDX) Given "Buy" Rating at BTIG ResearchSeptember 20, 2025 | marketbeat.comSyndax announces updated NCCN Guidelines for AMLSeptember 19, 2025 | msn.comSyndax’s Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute ...September 19, 2025 | finance.yahoo.comSyndax's Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid LeukemiaSeptember 19, 2025 | globenewswire.comSyndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Down 4.8% - Time to Sell?September 17, 2025 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Given "Buy" Rating at Stifel NicolausSeptember 12, 2025 | marketbeat.comZimmer Partners LP Buys Shares of 213,159 Syndax Pharmaceuticals, Inc. $SNDXSeptember 11, 2025 | marketbeat.comSyndax Pharmaceuticals, Inc. $SNDX Shares Bought by Exome Asset Management LLCSeptember 11, 2025 | marketbeat.comInsider Selling: Syndax Pharmaceuticals (NASDAQ:SNDX) CEO Sells 157,307 Shares of StockSeptember 10, 2025 | marketbeat.comSyndax resumed with Buy at Stifel on newly launched drugsSeptember 10, 2025 | msn.comPolar Asset Management Partners Inc. Purchases 21,630 Shares of Syndax Pharmaceuticals, Inc. $SNDXSeptember 9, 2025 | marketbeat.comStocks To Watch: Syndax Pharmaceuticals Sees Relative Strength Rating Jump To 84September 8, 2025 | msn.comSyndax Pharmaceuticals, Inc. $SNDX Shares Purchased by Parkman Healthcare Partners LLCSeptember 8, 2025 | marketbeat.comGranahan Investment Management LLC Has $6.76 Million Stake in Syndax Pharmaceuticals, Inc. $SNDXSeptember 7, 2025 | marketbeat.comGuggenheim Begins Coverage on Syndax Pharmaceuticals (NASDAQ:SNDX)September 6, 2025 | marketbeat.comSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)September 5, 2025 | globenewswire.com59,210 Shares in Syndax Pharmaceuticals, Inc. $SNDX Purchased by Ieq Capital LLCSeptember 5, 2025 | marketbeat.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Recommendation of "Buy" by AnalystsSeptember 5, 2025 | marketbeat.comGuggenheim Initiates Coverage of Syndax Pharmaceuticals (SNDX) with Buy RecommendationSeptember 4, 2025 | msn.comDeep Dive Into Syndax Pharmaceuticals Stock: Analyst Perspectives (5 Ratings)September 4, 2025 | benzinga.comSyndax Pharmaceuticals, Inc. $SNDX Shares Purchased by Palo Alto Investors LPSeptember 4, 2025 | marketbeat.comSyndax Pharmaceuticals, Inc. $SNDX Shares Purchased by Invesco Ltd.September 4, 2025 | marketbeat.comPoint72 Europe London LLP Takes Position in Syndax Pharmaceuticals, Inc. $SNDXSeptember 3, 2025 | marketbeat.comTrexquant Investment LP Reduces Holdings in Syndax Pharmaceuticals, Inc. $SNDXSeptember 3, 2025 | marketbeat.comSyndax Pharmaceuticals, Inc. $SNDX Shares Sold by Wellington Management Group LLPSeptember 3, 2025 | marketbeat.comSyndax Pharmaceuticals, Inc. (SNDX) Presents At Citi's Biopharma Back To School Conference TranscriptSeptember 2, 2025 | seekingalpha.comTema Etfs LLC Acquires New Position in Syndax Pharmaceuticals, Inc. $SNDXAugust 31, 2025 | marketbeat.comNuveen LLC Acquires Shares of 224,153 Syndax Pharmaceuticals, Inc. $SNDXAugust 31, 2025 | marketbeat.comRussell Investments Group Ltd. Acquires 88,591 Shares of Syndax Pharmaceuticals, Inc. $SNDXAugust 30, 2025 | marketbeat.comWalleye Capital LLC Lowers Stake in Syndax Pharmaceuticals, Inc. $SNDXAugust 29, 2025 | marketbeat.comSyndax Announces Participation in September Investor ConferencesAugust 26, 2025 | globenewswire.comCandriam S.C.A. Has $5.53 Million Stock Position in Syndax Pharmaceuticals, Inc. $SNDXAugust 24, 2025 | marketbeat.comSyndax Pharmaceuticals, Inc. $SNDX Shares Bought by Aberdeen Group plcAugust 24, 2025 | marketbeat.comDeutsche Bank AG Has $2.52 Million Position in Syndax Pharmaceuticals, Inc. $SNDXAugust 22, 2025 | marketbeat.comDennis Podlesak Sells 19,200 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) StockAugust 20, 2025 | marketbeat.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Director Dennis Podlesak Sells 19,200 SharesAugust 20, 2025 | marketbeat.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Acquired by Algert Global LLCAugust 19, 2025 | marketbeat.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Director Sells $298,368.00 in StockAugust 19, 2025 | insidertrades.comBTIG Raises Syndax Pharmaceuticals (SNDX) PT to $56 Following Strong Q2 Revenue from Revuforj, NiktimvoAugust 18, 2025 | msn.comSyndax Pharmaceuticals (NASDAQ:SNDX) Trading Up 4.4% - Time to Buy?August 16, 2025 | marketbeat.comSyndax Pharmaceuticals (SNDX) Is Up 15.8% After Revenue Surges in Q2 2025 Results Has Sentiment Shifted?August 15, 2025 | finance.yahoo.comAigen Investment Management LP Buys Shares of 24,158 Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)August 15, 2025 | marketbeat.comSyndax Pharmaceuticals: A Tale Of Two Drug LaunchesAugust 13, 2025 | seekingalpha.comSyndax Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:SNDX)August 13, 2025 | marketbeat.comFDA Priority Review and Revenue Growth Drive Short-Term Upswing for Syndax PharmaceuticalsAugust 13, 2025 | insidermonkey.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Recommendation of "Buy" by BrokeragesAugust 11, 2025 | marketbeat.comAnalysts Just Made A Dazzling Upgrade To Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) ForecastsAugust 10, 2025 | finance.yahoo.comSyndax Pharmaceuticals’ Earnings Call Highlights Robust GrowthAugust 9, 2025 | theglobeandmail.com Get Syndax Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SNDX Media Mentions By Week SNDX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SNDX News Sentiment▼0.311.02▲Average Medical News Sentiment SNDX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SNDX Articles This Week▼86▲SNDX Articles Average Week Get the Latest News and Ratings for SNDX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Syndax Pharmaceuticals and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies TGTX News PTCT News KRYS News ACLX News ARWR News ACAD News MENS News PCVX News PTGX News ADMA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SNDX) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syndax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Syndax Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SNDX Stock Alerts